EI
ELDN icon

EAM Investors’s Eledon Pharmaceuticals ELDN Stock Holding History

EAM Investors’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-109,555
Closed -$371K – 268
2025
Q1 		$371K Hold
109,555
– – 0.06% 240
2024
Q4 		$451K Buy
+109,555
New +$432K 0.06% 250

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

EAM Investors's ELDN Position: Q2 2025 in Review

EAM Investors sold out of Eledon Pharmaceuticals (ELDN) in Q2 2025, closing a stake of 109,555 shares — an estimated $371K sold.

EAM Investors first reported a position in ELDN in Q4 2024 and held it in 2 quarters. The position peaked at $451K in Q4 2024. 85 funds tracked by Wall St. Rank hold ELDN as of Q2 2025.

  • EAM Investors reported no remaining Eledon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • EAM Investors sold 109,555 Eledon Pharmaceuticals shares in Q2 2025, an estimated $371K.
  • EAM Investors first reported a position in Eledon Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • EAM Investors's Eledon Pharmaceuticals position peaked at $451K in Q4 2024.
  • 85 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2025.

Based on EAM Investors's 13F filing for Q2 2025, filed 12 Aug 2025.